RT Journal Article
SR Electronic
T1 Characterising severe traumatic brain injury from fresh cerebral biopsy in living patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.27.21265411
DO 10.1101/2021.10.27.21265411
A1 Ping K. Yip
A1 Shumaila Hasan
A1 Christopher E.G. Uff
YR 2021
UL http://medrxiv.org/content/early/2021/10/28/2021.10.27.21265411.abstract
AB Traumatic brain injury (TBI) is one of the most complex disorder in the most complex organ in the body and current classifications of mild, moderate and severe often fail to capture this complexity. Although the mainstay of prognosis involves several clinical classification systems, these systems are confined to macroscopic analysis. Therefore, we aim to use immunohistochemical examination of fresh brain biopsy samples to study the cellular and molecular changes caused by severe TBI.Twenty-five adult patients suffering severe TBI were recruited into the Severe Head Injury Brain Analysis (SHIBA) study. Fresh brain biopsies obtained prior intracranial pressure (ICP) monitor insertion or during craniotomy underwent immunohistochemical analysis using the neuronal marker (NeuN), dendritic marker (MAP2), vascular markers (claudin-5 and vWF), and neuroinflammation markers (Iba1 and P2Y12) to investigate the injury severity at microscopic level.Obtaining brain biopsy from the twenty-five patients in the study did not cause any additional burden to patient’s standard care and there were no adverse effects. The mean (± SD) Glasgow Outcome Scale-Extended (GOS-E) 3-months after injury was 4.0 (± 2.7), consisting of 64% unfavourable outcomes and 36% favourable outcomes. Immunostaining of brain tissue revealed various qualitative changes resulting in neuronal injury, dendritic injury, neurovascular injury, and neuroinflammation, which we classified into 4 subgroups for each injury type using the newly devised Yip, Hasan and Uff (YHU) grading system. Using this grading scale, patients with a total YHU grade of ≥ 11, 100% (n=11) had a GOS-E of ≤ 4, including death (54.5%), vegetative state (18.2%) and severe disability (27.3%) 3-months post injury. In contrast, those with a YHU grade of ≤ 8, 100% (n=8) had a GOS-E of 5 or higher, indicating a favourable outcome. Linear regression showed a significant negative correlation between the GOS-E and neuronal injury (R2 =0.240, p= 0.0129), dendritic injury (R2 =0.430, p= 0.0004), neurovascular injury (R2 =0.538, p<0.0001), and neuroinflammation (R2 =0.361, p= 0.0015).Brain biopsy in severe TBI is a simple and safe procedure. Furthermore, immunofluorescence staining enables classification of this heterogeneous patient population into various categories of injury severity based on the cellular and molecular pathophysiology according to the YHU grading system. This new grading scale should facilitate a more precise diagnosis, similar to what is currently standard in oncology, allowing earlier and more accurate prognosis than current grading systems, thereby adding to the arsenal of resources available to guide clinical decision making in treating patients with severe TBI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received towards this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the London-Camden & Kings Cross Research Ethics Committee (REC ref: 20/LO/0074) and this application was supported by a patient and public involvement project where >90% of participants were supportive of brain biopsy in TBI(Hasan et al., 2019 Emerg. Med. Int.).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.EVDExternal ventricular drainGCSGlasgow coma scaleGOS-EGlasgow Outcome Scale-ExtendedIba1ionized calcium-binding adaptor molecule 1ICPIntracranial pressureIHCImmunohistochemistryIHPIndependent Healthcare ProfessionalINRInternational normalized ratioMAP2Microtubule-associated protein-2NeuNNeuronal nuclear proteinOCTOptimal cutting temperatureSHIBASevere Head Injury Brain AnalysisTBITraumatic brain injuryvWFvon Willebrand factorYHUYip, Hasan and Uff